Results 311 to 320 of about 672,024 (402)

C-Reactive Protein in Immune Checkpoint Inhibitor-Associated Colitis: A Scoping Review of Evidence and Knowledge Gaps. [PDF]

Cancer Manag Res
Ohta R, Ryu Y, Tanaka K, Sano C, Hayashi H.   +4 more
europepmc   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, EarlyView.
What's New? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

Modified Pulsatilla decoction alleviates DSS-induced colitis in mice by modulating gut microbiota and promoting IL-10 and IL-22 expression. [PDF]

BMC Complement Med Ther
Hu CT, Liu JY, Chen HY, Lin LJ, Lee MS, Peng WH, Lin MK.   +6 more
europepmc   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

The protective role of Lactobacillus reuteri in a DSS-induced ulcerative colitis mouse model. [PDF]

PLoS One
Nazari M, Goodarzi R, Yazdan Panah A, Amiri I, Bagheri Y, Asghari B.   +5 more
europepmc   +1 more source

A Dual Action of Everolimus in Ulcerative Colitis: Blocking CLEC4E‐Driven Inflammation and Remodeling the Gut Microbiota‐Metabolite Axis

iMetaMed, EarlyView.
Graphical abstract of the major mechanisms of Everolimus in ulcerative colitis: Everolimus, a selective mTORC1 inhibitor, protects against ulcerative colitis through a dual mechanism. First, Eve directly suppresses CLEC4E/Syk/NF‐κB signaling, thereby reducing pro‐inflammatory cytokine production and preserving intestinal barrier integrity.
Jing Chen, Min Li, Wenyan Sun, Yuyun Chen, Yu Sheng, Cuihua Lu, Zhaoxiu Liu   +6 more
wiley   +1 more source

Weizmannia coagulans XY2 Mitigates Copper Neurotoxicity via Gut–Brain Axis Modulation of Tryptophan Metabolism and Oxidative‐Inflammatory Crosstalk

iMetaOmics, EarlyView.
Copper interferes with tryptophan metabolism and 5‐HT levels by modulating intestinal flora. Intestinal barrier breakdown and inflammatory response trigger nerve damage under copper exposure. W. coagulans XY2 alleviates copper‐induced neurotoxicity by targeting a multi‐dimensional “tryptophan metabolism‐antioxidant defense‐gut‐brain axis” network.
Yufang Gao, Xiaodong Zheng, Fujie Yan
wiley   +1 more source

Pharmacokinetic profiles of Moutan Cortex after single and repeated administration in a dinitrobenzene sulfonic acid-induced colitis model. [PDF]

PLoS One
Kim JH, Jeong JS, Kim JW, Chung EH, Lee SH, Ko JW, Hwang YH, Kim TW.   +7 more
europepmc   +1 more source

iMeta Conference 2025: Creating high‐impact international journals

iMeta, EarlyView.
The iMeta Conference 2025, part of the iMeta Conference series, themed “Creating High‐Impact International Journals,” held at the Huangjiahu Campus of Hubei University of Chinese Medicine from August 23rd to 25th, 2025, and focused on frontier topics such as microbiology, medicine, traditional Chinese medicine, botany, and research career development ...
Zhihao Zhu, Lin Zhang, Xiaofang Yao, Meiyin Zeng, Yao Wang, Hao Luo, Yuanping Zhou, Tianyuan Zhang, Jiani Xun, Defeng Bai, Haifei Yang, Shanshan Xu, Yang Zhou, Yunyun Gao, Jinbo Xu, Wei Han, ZiAng Shen, Bangzhou Zhang, Tengfei Ma, Xiu‐Lin Wan, Chuang Ma, Fengjiao Hui, Hao Bai, Lijing Bai, Qing Bai, Qiangguo Bao, Guodong Cao, Peng Cao, Qiqi Cao, Hu Chen, Jiawen Chen, Jiaxu Chen, Lihua Chen, Tingting Chen, Yi Chen, Haipeng Cui, Shaoxing Dai, Xi‐Jian Dai, Xiaofeng Dai, Yanqi Dang, Lei Deng, Yun Deng, Xia Ding, Binhua Dong, Ling Dong, Shujie Dou, Hongzhi Du, Zhencheng Fang, Xiaoxiao Feng, Min Fu, Yuan Gao, Wenping Gong, Xiang Guo, Wenjie Han, Zikai Hao, Zheng‐Guo He, Haibo Hu, Haiming Hu, Xuefei Hu, Liang Huang, Xianya Huang, Xueting Huang, Haochen Hui, Dingjiacheng Jia, Aimin Jiang, Di Jiang, Kun Jiang, Dewei Jiang, Ying Jin, Kunyang Lai, Chun Li, Feng Li, Fuyong Li, Jing Li, Juan Li, Junling Li, Kui Li, Ling Li, Moli Li, Peiwu Li, Peng Li, Runze Li, Shengnan Li, Shujin Li, Wanting Li, Wenting Li, Xiaojing Li, Xinrui Li, Xuemeng Li, Qiqi Liang, Xiaoping Liao, Boyang Liu, Canzhao Liu, Chang Liu, Duanrui Liu, Furong Liu, Jianjun Liu, Jinyao Liu, Siqi Liu, Tianyang Liu, Wenjuan Liu, Yan Liu, Yang Liu, Yi Liu, Yuan Liu, Yunhuan Liu, Zhipeng Liu, Zhiyong Liu, Xin Lu, Xiao Luo, Guanju Ma, Jialin Meng, Yuanfa Meng, Runyu Miao, Linxuan Miao, Yawen Ni, Dongze Niu, Tingting Niu, Hongzhao Pan, Guoqiang Qin, Tiantian Qiu, Yueping Qiu, Hui Qu, Linghang Qu, Na Ren, Qiang Sun, Run Shang, Peize She, Xihui Shen, Bohan Shi, You Shu, Jiawei Song, Weibin Song, Qi Su, Qingzhu Sun, YuPing Sun, Zijin Sun, Bufu Tang, Deqin Tang, Hua Tang, Yongfu Tao, Teng Teng, Yanye Tu, Cheng Wang, Hui Wang, Yunhao Wang, Chunli Wang, Dingjie Wang, Gang Wang, Jin Wang, Kaiyi Wang, Mingbang Wang, Shan Wang, Shixiang Wang, Xiaojie Wang, Xing‐Chang Wang, Yunzhe Wang, Jiale Wang, Zheng Wang, Weijie Wang, Yongjun Wei, Wei Xu, Fan Wu, Junling Wu, Shijuan Wu, Jian Xiao, Weihua Xiao, Yang Xiao, Xi Xiong, Xue Xiong, Feng Xu, Junyu Xu, Wen Xu, Jun Xu, Yao Xu, Jun Yan, Lutian Yao, Jia Yang, Lulu Yang, Xingzhen Yang, Naiyi Yin, Hua You, Min You, Ting Yu, Yongyao Yu, Renqiang Yu, Shuofeng Yuan, Chaoxiong Yue, Xiaoya Zeng, Andong Zha, Leilei Zhai, Chi Zhang, Dong Zhang, Hengguo Zhang, Heng Zhang, Hongyu Zhang, Jiahao Zhang, Jinyang Zhang, Lishan Zhang, Qi Zhang, Xiang Zhang, Xiangyu Zhang, Xuelei Zhang, Yancong Zhang, Yuan Zhang, Zhenyu Zhang, Jiwei Zhao, Jingxuan Zhao, Kai Zhao, Mingjuan Zhao, Yi Zhao, Yunxiang Zhao, Jixin Zhong, Ling Zhong, Xiangjian Zhong, Dan Zhou, Wei Zhou, Wen Zhou, Yiqian Zhou, Zhemin Zhou, Shiquan Zhu, Shuang‐Jiang Liu, Suyin Feng, Shuangxia Jin, Chuanxing Xiao, Ziheng Wang, Peng Luo, Tong Chen, Gang Chen, Yong‐Xin Liu   +229 more
wiley   +1 more source

NCF2 as a Novel Diagnostic Biomarker in Ulcerative Colitis: Linking Macrophage Infiltration to Immune Dysregulation via Multi-Omics Analysis. [PDF]

J Inflamm Res
Zhang F, Zhu J, Liu H, Ye J, Li Y, Wang B.   +5 more
europepmc   +1 more source